News | 27 November 2025
Investors pile in as Cordance secures oversubscribed seed round for brain-cancer tech
The fresh capital will propel Cordance into its first-in-human clinical trial
The fresh capital will propel Cordance into its first-in-human clinical trial
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Renalyx will continue operating as an independent unit within the group
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
A key highlight will be Brenntag’s qualified amino acids portfolio
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The proposed transaction will be effected as a share swap
The company will soon be launching a new portfolio of products in this segment
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The non-dilutive financing includes three tranches
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Subscribe To Our Newsletter & Stay Updated
